advertisement
Sato K 19
Showing records 1 to 19 | Display all abstracts from Sato K84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Yamamoto K
Scientific reports 2019; 9: 19288
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Sato K
Current Eye Research 2020; 0: 1-10
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Yabana T
PLoS ONE 2019; 14: e0227078
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Nakagawa Y
Current Eye Research 2020; 0: 1-10
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Sato K
PLoS ONE 2019; 14: e0227078
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Kokubun T
Scientific reports 2019; 9: 19288
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Shiga Y
PLoS ONE 2019; 14: e0227078
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Omodaka K
Current Eye Research 2020; 0: 1-10
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Sato K
Scientific reports 2019; 9: 19288
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Asada H
Current Eye Research 2020; 0: 1-10
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Akaishi T
Scientific reports 2019; 9: 19288
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Himori N
PLoS ONE 2019; 14: e0227078
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Shimazaki A
Scientific reports 2019; 9: 19288
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Fujii S
Current Eye Research 2020; 0: 1-10
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Omodaka K; Nakazawa T
PLoS ONE 2019; 14: e0227078
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Masaki K
Current Eye Research 2020; 0: 1-10
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Nakamura M; Shiga Y
Scientific reports 2019; 9: 19288
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Nakazawa T
Current Eye Research 2020; 0: 1-10
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Tsuda S; Omodaka K; Saya H; Nakazawa T
Scientific reports 2019; 9: 19288
